Urine Extracellular Vesicle GATA2 mRNA Discriminates Biopsy Result in Men with Suspicion of Prostate Cancer
JungReem Woo, Sandra Santasusagna, Joshua Banks, S. Pastor-Lopez, Kamlesh K. Yadav, Marc Carceles‐Cordon, Ana Dominguez-Andres, Robert B. Den, Lucia R. Languino, Raffaella Pippa, Costas D. Lallas, Grace Lu‐Yao, William Kevin Kelly, Karen E. Knudsen, Verónica Rodríguez-Bravo, Ashutosh Tewari, Josep María Prats, Benjamin E. Leiby, Leonard G. Gomella, Josep Domingo‐Domenech
Abstract
PURPOSE: Prostate specific antigen has limited performance in detecting prostate cancer. The transcription factor GATA2 is expressed in aggressive prostate cancer. We analyzed the predictive value of urine extracellular vesicle GATA2 mRNA alone and in combination with a multigene panel to improve detection of prostate cancer and high risk disease. MATERIALS AND METHODS: RG (GAPT-E) was tested in both cohorts. RESULTS: RG). A GAPT-E score for high grade prostate cancer would avoid 92.1% of unnecessary prostate biopsies, compared to 61.9% when a PT-E score is used. CONCLUSIONS: Urine extracellular vesicle GATA2 mRNA analysis improves the detection of high risk prostate cancer and may reduce the number of unnecessary biopsies.